RAS
Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial
Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.